Menu

Sign in

Sign in

Contact us

Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

CTG Catapult opens its new unique cell and gene therapy plant in the U.K.

CTG Catapult opens its new unique cell and gene therapy plant in the U.K.

The government-funded Cell and Gene Therapy Catapult opened its $83.

Neurocrine presents positive analysis of Phase III Ingrezza data

Neurocrine presents positive analysis of Phase III Ingrezza data

Neurocrine Biosciences has presented a new analysis of data from the KINECT 3 Phase III trial of Ingrezza (valbenazine) showing improved outcomes for tardive dyskinesia (TD) patients.

Availability of orphan medicines varies between European countries

Availability of orphan medicines varies between European countries

There are differences in the availability of orphan medicines between different European countries, a new study from the University of Eastern Finland shows.

DNA. DNA is most commonly found in the well-known double helix shape, but new research shows it can take another form

DNA. DNA is most commonly found in the well-known double helix shape, but new research shows it can take another form

DNA. One of the most familiar shapes in science is DNA’s double helix structure.

FDA Approves Akynzeo for Injection

FDA Approves Akynzeo for Injection

Lugano, Switzerland April 20, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.

FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE.

Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co.

FDA hits Hong Kong OTC drugmaker with warning letter

FDA hits Hong Kong OTC drugmaker with warning letter

The FDA issued a warning letter to Hong Kong-based over-the-counter drugmaker Luen Wah Medicine, citing the company for not testing the identity and strength of each active ingredient in its products.

Squeezed Mylan axing 500 jobs in West Virginia to 'right-size' massive plant

Squeezed Mylan axing 500 jobs in West Virginia to 'right-size' massive plant

To "right-size" what Mylan says is one of the world's largest pharmaceutical plants, the generic drugmaker is laying off about 500 employees in Morgantown, West Virginia.

UK bans Sanofi epilepsy drug without pregnancy prevention plan

UK bans Sanofi epilepsy drug without pregnancy prevention plan

LONDON (Reuters) - A Sanofi drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they a...

Jilted Akorn sues Fresenius over deal termination

Jilted Akorn sues Fresenius over deal termination

FRANKFURT (Reuters) - U.

Two new lung cancer medicines offer hope

Two new lung cancer medicines offer hope

Late-stage lung cancer patients who have built up a tolerance to some drugs may have new hope thanks to two domestically developed medicines, doctors from Shanghai Chest Hospital said on Thursday.

45 46 47 484950 51 52 53

0 items in Cart

Cart Subtotal:

You will be able to Pay Online or Request a Quote